INFLUENCE OF ROUTE OF ADMINISTRATION ON PHYSIOLOGICAL AVAILABILITY OF LEVODOPA IN DOGS

被引：24

作者：

COTLER, S ^{[1
]}

HOLAZO, A ^{[1
]}

BOXENBAUM, HG ^{[1
]}

KAPLAN, SA ^{[1
]}

机构：

[1] HOFFMANN LA ROCHE INC,DEPT BIOCHEM & DRUG METAB,NUTLEY,NJ 07110

来源：

JOURNAL OF PHARMACEUTICAL SCIENCES | 1976年 / 65卷 / 06期

关键词：

D O I：

10.1002/jps.2600650607

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：822 / 827

页数：6

共 29 条

[1]

BARBEAU A, 1971, CLIN PHARMACOL THER, V12, P353

[2] INCREASE OF CEREBRAL CATECHOLAMINES CAUSED BY 3,4-DIHYDROXYPHENYLALANINE AFTER INHIBITION OF PERIPHERAL DECARBOXYLASE [J].

BARTHOLINI, G ;

BURKARD, WP ;

PLETSCHER, A ;

BATES, HM .

NATURE, 1967, 215 (5103) :852-+

[3] ABSORPTION AND METABOLISM OF A STANDARD ORAL DOSE OF LEVODOPA IN PATIENTS WITH PARKINSONISM [J].

BERGMANN, S ;

CURZON, G ;

FRIEDEL, J ;

GODWINAU.RB ;

MARSDEN, CD ;

PARKES, JD .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1974, 1 (05) :417-424

[4] METABOLISM AND ABSORPTION OF L-3,4 DIHYDROXYPHENYLALANINE IN PATIENTS WITH PARKINSONS DISEASE [J].

BIANCHINE, JR ;

CALIMLIM, LR ;

MORGAN, JP ;

DUJUVNE, CA ;

LASAGNA, L .

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1971, 179 (JUL6) :126-+

[5] MODERN TREATMENT OF PARKINSONISM [J].

BIRKMAYER, W ;

NEUMAYER, E .

ZEITSCHRIFT FUR NEUROLOGIE, 1972, 202 (04) :257-+

[6] L-DOPA LEVEL IN PLASMA, PRIMARY CONDITION FOR KINETIC EFFECT [J].

BIRKMAYER, W ;

DANIELCYK, W ;

NEUMAYER, E ;

RIEDERER, P .

JOURNAL OF NEURAL TRANSMISSION, 1973, 34 (02) :133-143

[7] STATISTICAL ESTIMATIONS IN PHARMACOKINETICS [J].

BOXENBAU.HG ;

RIEGELMA.S ;

ELASHOFF, RM .

JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1974, 2 (02) :123-148

[8]

BOYES RN, 1970, J PHARMACOL EXP THER, V174, P1

[9] LEVODOPA - REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USES WITH PARTICULAR REFERENCE TO PARKINSONISM [J].

BROGDON, RN .

DRUGS, 1971, 2 (04) :262-+

[10]

CARLSSON A, 1972, ACTA NEUROL SCAND, V48, P11

← 1 2 3 →